Literature DB >> 2877981

Cross-linking site in fibrinogen for alpha 2-plasmin inhibitor.

S Kimura, N Aoki.   

Abstract

A plasma proteinase inhibitor, alpha 2-plasmin inhibitor (alpha 2PI), is cross-linked with alpha chain of fibrin(ogen) by activated coagulation Factor XIII (plasma transglutaminase). alpha 2PI serves only as a glutamine substrate (amine acceptor) for activated Factor XIII in the cross-linking reaction, and the cross-linking occurs between Gln-2 of the alpha 2PI molecule and a lysine residue (amine donor) of fibrin(ogen) alpha chain, whose position was investigated. alpha 2PI and fibrinogen were reacted by activated Factor XIII. The resulting alpha 2PI fibrinogen A alpha chain complex was separated and subjected to two cycles of Edman degradation using phenyl isothiocyanate for the first cycle and dimethylaminoazobenzene-isothiocyanate for the second cycle. The aqueous phase after the cleavage stage of the second cycle, containing dimethylaminoazobenzene-thiohydantoin-Gln cross-linked with A alpha chain, was subjected to CNBr fragmentation and tryptic digestion. Only one of the peptides was found to have the peak of absorbance at 420 nm, indicating the presence of dimethylaminoazobenzene-thiohydantoin-Gln in that peptide. The peptide was identified as corresponding to residues Asn-290-Arg-348 of A alpha chain by analyses of the NH2-terminal amino acid sequence and amino acid composition. The peptide contains a single lysine at position 303, indicating that Lys-303 of fibrinogen A alpha chain is the lysine residue that forms a cross-link with Gln-2 of alpha 2PI.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877981

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Organization of the human alpha 2-plasmin inhibitor gene.

Authors:  S Hirosawa; Y Nakamura; O Miura; Y Sumi; N Aoki
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

2.  Identification of respective lysine donor and glutamine acceptor sites involved in factor XIIIa-catalyzed fibrin α chain cross-linking.

Authors:  Weixun Wang
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

3.  Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.

Authors:  Galina Tsurupa; Sergiy Yakovlev; Patrick McKee; Leonid Medved
Journal:  Biochemistry       Date:  2010-09-07       Impact factor: 3.162

4.  The human alpha(2)-plasmin inhibitor: functional characterization of the unique plasmin(ogen)-binding region.

Authors:  Simon S Gerber; Sofia Lejon; Michael Locher; Johann Schaller
Journal:  Cell Mol Life Sci       Date:  2010-01-29       Impact factor: 9.261

Review 5.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

Review 6.  Fibrinolysis and the control of blood coagulation.

Authors:  John C Chapin; Katherine A Hajjar
Journal:  Blood Rev       Date:  2014-09-16       Impact factor: 8.250

7.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

8.  The kidney is a major site of alpha(2)-antiplasmin production.

Authors:  P A Menoud; N Sappino; M Boudal-Khoshbeen; J D Vassalli; A P Sappino
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus.

Authors:  E J Dunn; H Philippou; R A S Ariëns; P J Grant
Journal:  Diabetologia       Date:  2006-03-16       Impact factor: 10.122

Review 10.  State of the art in factor XIII laboratory assessment.

Authors:  Michael A Durda; Alisa S Wolberg; Bryce A Kerlin
Journal:  Transfus Apher Sci       Date:  2018-08-04       Impact factor: 1.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.